glp-1 shortage news today 2025 shortages november FDA finalizes decision to end Lilly's GLP-1 shortage, analysts predict Novo will be next Who Gets the Shot? GLP-1

The rising incidence of metabolic disorders is generating considerable demand for advanced therapeutic solutions

We would be grateful if you could share your thoughts about our medical spa with others

For Wegovy, injection site reactions were reported in 2.4% of patients compared to 1.0% with placebo

Endothelial injury generated directly by intracellular viral replication and by ACE2 downregulation, exposing cells to angiotensin II in the absence of the modulator effects of angiotensin 17 (270, 271), and vascular chronic inflammation promoting the development of tissue macrophages overloaded by cholesterol (foam cells), both increase the possibility of acquiring a severe COVID-19 infection (170, 209, 258, 259, 272, 273)